Patents Assigned to University of North Texas Health Science Center at Fort
Worth
-
Patent number: 11525834Abstract: The present invention includes methods and kits for the diagnosing a neurological disease within primary care settings comprising: obtaining a blood test sample from a subject, measuring IL-7 and TNF? biomarkers in the blood sample, comparing the level of the one or a combination of biomarkers and neurocognitive screening tests with the level of a corresponding one or combination of biomarkers in a normal blood sample and neurocognitive screening tests, and predicting that an increase in the level of the blood test sample in relation to that of the normal blood sample indicates that the subject is likely to have a neurological disease.Type: GrantFiled: July 9, 2014Date of Patent: December 13, 2022Assignees: University of North Texas Health Science Center at Fort Worth, Board of Regents, The University of Texas SystemInventors: Sid E. O'Bryant, Robert C. Barber, Guanghua Xiao, Dwight German
-
Patent number: 11172731Abstract: Dual-layer insole apparatuses for diabetic foot lesion prevention and related methods are provided. Some insole apparatuses have a body defining a plurality of cavities configured to be coupled to a fluid source. The fluid source can deliver fluid to vary internal pressures of the cavities. The body further defines an insole-shaped structure.Type: GrantFiled: November 28, 2017Date of Patent: November 16, 2021Assignees: The Board of Regents of the Universsity of Texas Systems, The University of North Texas Health Science Center At Fort WorthInventors: Muthu B. J. Wijesundara, Wei Carrigan, Ryan Landrith, Metin Yavuz
-
Patent number: 10774328Abstract: The present invention includes a composition and method for the treatment of an eye disease comprising a therapeutically effective amount of an autophagy stimulator that treats or slows the progression of the eye disease by enhancing or stimulating autophagy or correcting an autophagy deficiency.Type: GrantFiled: July 11, 2017Date of Patent: September 15, 2020Assignee: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTHInventor: Gulab Zode
-
Patent number: 10766866Abstract: The present invention related to compounds, compositions, methods of use, and processes for preparing compound which are useful as deterrents for terrestrial arthropods and marine organisms.Type: GrantFiled: October 30, 2018Date of Patent: September 8, 2020Assignee: University of North Texas Health Science Center at Fort WorthInventor: John A. Schetz
-
Publication number: 20190234967Abstract: The present invention includes a method for excluding patients from the need for further analysis of Alzheimer's Disease comprising: obtaining a blood or serum sample from a patient in a primary care setting; determining the expression levels of at least 4 of the following proteins: FABP, beta 2 microglobulin, PPY, soluble tumor necrosis factor receptor 1 (sTNFR1), CRP, VCAM-1, thrombopoietin, ?2 macroglobulin, eotaxin 3, tumor necrosis factor-alpha (TNF-?), tenascin C (TNC), IL-5, IL-6, IL-7, IL-10, IL-18, 1309, Factor VII, thymus and activation-regulated chemokine (TARC), serum amyloid A (SAA), and intercellular cell-adhesion molecule-1 (ICAM-1); comparing the level of expression from the sample with a statistically locked-down, multi-ethnic, broad age spectrum statistical sample; and determining if the patient is excluded from further testing for Alzheimer's Disease, thereby eliminating the need for further testing of the patient.Type: ApplicationFiled: June 22, 2017Publication date: August 1, 2019Applicant: University of North Texas Health Science Center at Fort WorthInventor: Sid E. O'Bryant
-
Patent number: 10195297Abstract: Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 (165Ho) and dysprosium-164 (164Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).Type: GrantFiled: November 3, 2017Date of Patent: February 5, 2019Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTHInventors: Anthony J. Di Pasqua, Kenneth J. Balkus, Jr., Imalka S. Munaweera, Yi Shi
-
Patent number: 9808543Abstract: Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 (165Ho) and dysprosium-164 (164Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).Type: GrantFiled: January 20, 2015Date of Patent: November 7, 2017Assignees: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Anthony J. Di Pasqua, Kenneth J. Balkus, Jr., Imalka S. Munaweera, Yi Shi
-
Multiple-pulse pumping for enhanced fluorescence detection and molecular imaging in cells and tissue
Patent number: 9612245Abstract: The present invention includes a method and system for enhancing the signal-to-noise ratio in emission detection comprising: selecting a probe capable of at least one of fluorescence, phosphorescence, or delayed fluorescence in or about a sample that comprises interfering background signal; and exposing the probe to one or more controllable bursts, each burst comprising two or more pulses, wherein the one or more controllable bursts of high repetition energy pulses enhance the signal from the probe above that of the background signal.Type: GrantFiled: July 3, 2014Date of Patent: April 4, 2017Assignees: University of North Texas Health Science Center at Fort Worth, Texas Christian UniversityInventors: Ryan M. Rich, Ignacy Gryczynski, Julian Borejdo, Zygmunt Gryczynski -
Patent number: 9555011Abstract: The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell.Type: GrantFiled: April 7, 2015Date of Patent: January 31, 2017Assignee: University of North Texas Health Science Center at Fort WorthInventors: Arthur R. C. Braden, Jamboor K. Vishwanatha
-
Patent number: 9376315Abstract: The present invention provides partially fluorescent nanoparticles and methods of making and using the partially fluorescent nanoparticle having a nanoparticle with a matrix and a fluorescent dye dispersed in or about the matrix, wherein at least a portion of the fluorescent dye has been anisotropically bleached.Type: GrantFiled: February 17, 2011Date of Patent: June 28, 2016Assignee: University of North Texas Health Science Center at Fort WorthInventors: Zygmunt Gryczynski, Ignacy Gryczynski, Rafal Luchowski, Julian Borejdo
-
Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
Patent number: 9192598Abstract: A group of antimicrobial compounds shows effectiveness for preventing bacterial growth and bio film formation. In particular, the compounds are effective for preventing the growth of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (“MRSA”) bacteria. The compounds include naturally-occurring compounds such as linoleyl ethanolamide, noladin ether, and anandamide, and man-made compounds such as CP55,640 [(?)-cis-3-[2-Hydroxy-4-(l,l-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol] and O-2050 [(6aR,10aR)-3-(l-Methanesulfonylamino-4-hexyn-6-yl)-6a,7,10,1Oa-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran]. Because these antibacterial compounds have unique modes of action and/or unique chemical scaffolds compared to traditional antibiotics, they are extremely useful against bacteria having resistances to antibiotics.Type: GrantFiled: June 25, 2009Date of Patent: November 24, 2015Assignees: University of North Texas Health Science Center at Fort Worth, The Texas A&M University SystemInventors: John A. Schetz, Sally A. Hoger -
Patent number: 9138411Abstract: The present invention includes compositions and methods of making a nanoparticle composition comprising a polymeric core comprising one or more polymers and one or more active agents, and at least one layer of one or more lipids on the surface of the polymeric core; more specifically, the invention relates to the use of curcumin within such a lipid-polymer nanoparticle formulation for minimizing QT prolongation associated with curcumin in treatment of cancer.Type: GrantFiled: August 31, 2013Date of Patent: September 22, 2015Assignees: University of North Texas Health Science Center at Fort Worth, SignPath Pharma, Inc.Inventors: Amalendu Prakash Ranjan, Anindita Mukerjee, Jamboor K. Vishwanatha, Lawrence Helson
-
Patent number: 9023395Abstract: The present invention includes compositions and methods of making an activated polymeric nanoparticle for targeted drug delivery that includes a biocompatible polymer and an amphiphilic stabilizing agent non-covalently associated with a spacer compound that includes at least one electrophile that selectively reacts with any nucleophilic on a targeting agent and places the targeting agent on the exterior surface of a biodegradable nanoshell, wherein an active agent is loaded with the nanoshell.Type: GrantFiled: April 11, 2008Date of Patent: May 5, 2015Assignee: University of North Texas Health Science Center at Fort WorthInventors: Arthur R. C. Braden, Jamboor K. Vishwanatha
-
Patent number: 8895637Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.Type: GrantFiled: October 25, 2013Date of Patent: November 25, 2014Assignees: University of North Texas Health Science Center at Fort Worth, The Board of Regents of the University of Texas SystemInventors: John A. Schetz, Robert F. McMahon
-
Patent number: 8748608Abstract: Dopamine D3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, improved D3 receptor affinity and selectivity, as well as water solubility, is achieved. A series of linking-chain derivatives are disclosed wherein functionality such as OH or OAc groups have been introduced into the linking chain. In general, these modifications are well tolerated at D3 receptors and achieve high selectivity over D2 and D4 receptors.Type: GrantFiled: June 15, 2007Date of Patent: June 10, 2014Assignees: The United States of America as Represented by the Secretary of the Department of Health and Human Services, The University of North Texas Health Science Center at Fort WorthInventors: Amy Hauck Newman, Peter Grundt, George C. Cyriac, Robert Luedtke, Jianjing Cao
-
Patent number: 8734853Abstract: Disclosed are high density lipoprotein-nucleic acid particles, wherein the particles include (a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component. Also disclosed are pharmaceutical compositions that include a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region. Methods that concern the particles and pharmaceutical compositions of the present invention are also set forth, as well as kits.Type: GrantFiled: November 17, 2009Date of Patent: May 27, 2014Assignees: University of North Texas Health Science Center at Fort Worth, The Board of Regents, The University of Texas SystemInventors: Anil K. Sood, Andras G. Lacko, Gabriel Lopez-Berestein, Lingegowda S. Mangala, Walter J. McConathy, Laszlo Prokai, Maya P. Nair
-
Publication number: 20140051751Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.Type: ApplicationFiled: October 25, 2013Publication date: February 20, 2014Applicants: The Board of Regents of the University of Texas System, University of North Texas Health Science Center at Fort WorthInventors: John A. Schetz, Robert F. McMahon
-
Patent number: 8575230Abstract: Environmentally-friendly alternatives to organometallic antifoulants that are efficacious at preventing biofouling by organisms such as the zebra mussel. Preferred antifoulant compositions utilize compounds having a Lipophilic-Amide-Spacer-ElectroNegative (“LASEN”) structural motif, such as capsaicin, and compounds having a TetraHydroCannibinoid (“THC”) structural motif. The antifoulant compositions are non-toxic, and effective.Type: GrantFiled: April 16, 2008Date of Patent: November 5, 2013Assignees: University of North Texas Health Science Center at Fort Worth, The Board of Regents of the University of Texas SystemInventors: John A. Schetz, Robert F. McMahon
-
Publication number: 20120207857Abstract: The present invention includes compositions and method to improve the therapeutic index of anti-cancer agents using a novel anti-cancer agent and a modulator or potentiator thereofType: ApplicationFiled: April 4, 2012Publication date: August 16, 2012Applicant: University of North Texas Health Science Center at Fort WorthInventors: Wolfram Siede, Rouel S. Roque
-
Patent number: 8163692Abstract: Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of RalBP1 to create a proteoliposome. RalBP1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds, and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds. In addition, RalBP1 is effective for the protection and treatment of mammals against the effects of ionizing radiation.Type: GrantFiled: July 24, 2009Date of Patent: April 24, 2012Assignee: University of North Texas Health Science Center of Fort WorthInventors: Sanjay Awasthi, Sharad S. Singhal